The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

Media type: E-Article

Title: The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

Contributor: Puoti, Massimo; Cozzi-Lepri, Alessandro; Ancarani, Fausto; Bruno, Raffaele; Ambu, Silvia; Ferraro, Teresa; Tundo, Paolo; Santantonio, Teresa; Toti, Mario; Bonasso, Marino; Monforte, Antonella d'Arminio; Ancarani, F; Antonucci, G; Bonasso, M; Bruno, R; Cozzi-Lepri, A; Monforte, A d'Arminio; Luca, A De; Galli, M; Gennero, L; Girardi, E; Lipani, F; Marino, N; Milazzo, L; [...]

imprint: SAGE Publications, 2004

Language: English

DOI: 10.1177/135965350400900506

ISSN: 2040-2058; 1359-6535

Keywords: Infectious Diseases ; Pharmacology (medical) ; Pharmacology

Origination:

Footnote:

Description: We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [–81.1 mU/ml mean difference; 95% confidence intervals (95% CI): –30.3; –131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01–0.38, P=0.002] than those starting a lamivudine sparing-regimen.

Access State: Open Access

Search in field:

Recently searched for: